Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04925492 · ClinicalTrials.gov registry record · Phase 1
PET Imaging of Vaso-Occlusive Crisis (VOC) in SCD
A Phase 1 study of Sickle Cell Disease, sponsored by Enrico Novelli.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT04925492 is a Phase 1 study of Sickle Cell Disease that is actively recruiting participants, run by Enrico Novelli. The registered enrollment target is 20 participants, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04925492, a Phase 1 study of Sickle Cell Disease, is actively recruiting participants, sponsored by Enrico Novelli.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to find objective biomarkers of vaso-occlusion (blood vessel blockage) in people with SCD. Using information from earlier studies and work being done, researchers have developed a strategy to image VOC, using positron emission tomography (PET). The ability to see and measure VOC in SCD patients can help patient care, by showing when and how a VOC is occurring or going to occur. Studying this method will also help in future drug research, as it will allow researchers to deliver promising new medications that target hyper-adhesion and sickling in people with SCD.
Conditions Studied
Interventions
- RADIATION Positron Emission Tomography
- DRUG Cu-64]-LLP2A
Study Locations (1)
Pennsylvania
- UPMC - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2022-11-11 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04925492
The ClinicalTrials.gov registry entry for NCT04925492 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (93% lower). The listed sponsor is Enrico Novelli, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Sickle Cell Disease appearing as the primary indexed condition, and to 2 interventions - of which Positron Emission Tomography is the first listed.
NCT04925492 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04925492 about?
NCT04925492 is a clinical study titled "PET Imaging of Vaso-Occlusive Crisis (VOC) in SCD". The purpose of this study is to find objective biomarkers of vaso-occlusion (blood vessel blockage) in people with SCD. Using information from earlier studies and work being done, researchers have developed a strategy to image VOC, using positron emission tomography (PET). The ability to see and me...
What is the current status of trial NCT04925492?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2022-11-11. Estimated completion is 2027-12-31.
What conditions does trial NCT04925492 study?
This clinical trial studies the following conditions: Sickle Cell Disease.
What interventions are being tested in trial NCT04925492?
The interventions under investigation include: Positron Emission Tomography (RADIATION), Cu-64]-LLP2A (DRUG).
Who is sponsoring clinical trial NCT04925492?
This trial is sponsored by Enrico Novelli, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04925492 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
RECRUITING · Phase 1
-
Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies
RECRUITING · Phase 1
-
Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease
RECRUITING · Phase 1
-
Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease
RECRUITING · Phase 1
-
Methylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease
RECRUITING · Phase 1
-
Single-dose Pharmacokinetics of Pociredir in Participants With Sickle Cell Disease
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.